Stay updated with breaking news from Breaking Research. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Study data shows consistent independent risk stratification performance of DecisionDx-SCC in a novel cohort of patients with cutaneous squamous cell carcinoma and one or more risk factors ... | March 18, 2023
- Interim results from Phase 2 innovaTV 207 trial of tisotumab vedotin in head and neck cancer to be presented -- Initial Phase 1 dose-escalation data for SEA-TGT monotherapy in advanced malignancies to be disclosed -- Preclinical data and discovery research underscore Seagen’s mission to innovate through next-gener...
Three late-breaking presentations in vitiligo highlight new long-term data from the Phase 3 TRuE-V trials for Opzelura (ruxolitinib) cream and results from a Phase 2b study with povorcitinib (INCB54707)
Use of ruxolitinib cream (Opzelura) resulted in further improvement in facial and total body repigmentation at Week 52 Results will be featured as an oral presentation in a late-breaking abstract session
New data on ruxolitinib cream (Opzelura) in vitiligo and atopic dermatitis will be presented, including 52-week results from the Phase 3 TRuE-V vitiligo program which will be featured as a late-breaking